Abstract
Diabetic patients are frequently affected by coronary microvascular dysfunction (CMD) To date, no treatments specifically target this vascular damage. Therapeutic Management of CMD in Diabetes including correction of CV Risk Factors and classical pharmacological Options Diabetic patients with coronary microvascular dysfunction should minimize risk factors. It is recommended that all patients receive secondary prevention therapy, including aspirin and statins. Betablockers are recommended as a first-line therapy, and calcium channel blockers are recommended if beta-blockers do not achieve sufficient symptom control or are not tolerated. But recent experimental studies and some clinical investigations have produced data in favor of potential beneficial effects on coronary micro vessels caused by two classes of glucose- lowering drugs: glucagon-like peptide 1 (GLP-1)-based therapy and inhibitors of sodium-glucose cotransporter-2 (SGLT2).